LATS2 antibody orb6306 from Biorbyt

Product Specs
ItemLATS2 antibody
CompanyBiorbyt
Price Pricing Info Supplier Page
Catalog Numberorb6306
Quantity50 µl, 100 µl, 200 µl
ReactivityHuman, Mouse, Rat
TargetLATS2
Conjugate/TagUnconjugated
ApplicationsELISA, IF, IHC-Fr, IHC-P, WB
ClonalityPolyclonal
FormatLiquid
ImmunogenKLH conjugated synthetic peptide derived from human LATS2 (641-740/1088 aa)
Molecular Weight120 kDa
IsotypeIgG
HostRabbit
Concentration1mg/ml
NCBI Full Gene Namelarge tumor suppressor kinase 2, large tumor suppressor kinase 1
NCBI Gene Aliaseswts, WARTS, KPM
StorageShipped at 4°C. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles

Specifications/Features

Application Dilutions: WB=1:500-2000, IHC-P=1:100-500, IHC-F=1:100-500, IF=1:100-500, ELISA=1:5000-10000

Add to Compare List

Biorbyt

7, Signet Court

Swann Road

Cambridge, Cambridgeshire CB5 8LA

United Kingdom

Phone: +44(0)1223 815 212
+44(0)1223 280 240 (fax)
+44(0)1223 280 240

Email: info@biorbyt.com
support@biorbyt.com
accounts@biorbyt.com

Company Profile

Website: https://www.biorbyt.com/

(1) Hypoxia-Induced Placenta-Specific microRNA (miR-512-3p) Promotes Hepatocellular Carcinoma Progression by Targeting Large Tumor Suppressor Kinase 2OncoTargets and therapyJanuary 1, 2020Zhang B, Huang L, Tu J, Wu T.

(2) Lats1 and Lats2 are required for the maintenance of multipotency in the Müllerian duct mesenchymeDevelopment (Cambridge, England)October 18, 2019St-Jean G, Tsoi M, Abedini A, Levasseur A, Rico C, Morin M, Djordjevic B, Miinalainen I, Kaarteenaho R, Paquet M, et al.doi:10.1242/dev.180430 Antibodies used include LATS1 at 1:100-1:500 (SC-28223; Santa Cruz Biotechnology), LATS2 at 1:600 (orb6306; Biorbyt), YAP at 1:200 (4912S; Cell Signaling Technology), TAZ at 1:500 (4883S; Cell Signaling Technology),

(3) Huyang yangkun formula protects against 4-Vinylcyclohexene diepoxide-induced premature ovarian insufficiency in rats via the Hippo-JAK2/STAT3 signaling pathwayBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapieAugust 1, 2019Xie L, Wu S, Cao D, Li M, Liu J, Nie G, Li Y, Yang H.

(4) miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2International journal of oncologyDecember 1, 2018Han LL, Yin XR, Zhang SQ.

(5) miR-650 Promotes the Metastasis and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 ExpressionCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacologyJanuary 1, 2018Han LL, Yin XR, Zhang SQ.

(6) Targeted ablation of alpha-crystallin-synthesizing cells produces lens-deficient eyes in transgenic miceDevelopment (Cambridge, England)March 1, 1989Kaur S, Key B, Stock J, McNeish JD, Akeson R, Potter SS.

(7) [Basic concepts and recent progress on the effects of flight on the central nervous system. 1]Minerva medicaSeptember 8, 1979Felici C.

(8) [Prognosis of masticatory organ anomalies of the prognathism group by means of teleradiography]Czasopismo stomatologiczneJanuary 1, 1978Lopatyńska-Kawako J.

(9) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-1975The New England journal of medicineAugust 14, 1975

Be the First to Write a Review!

LATS2 antibody

LATS2 antibody from Biorbyt

Description

Specifications/Features

Biorbyt

Citations (9)

Reviews

LATS2 antibody from Biorbyt

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map